GlassScriptPhysician profile
Ajay K Kandra
NPI 1538347521
$407,752.61
in general payments reported to CMS, 2019-2025
47 companies · $118K in 2025
The $118K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,292 · 2021: $17K · 2022: $142K · 2023: $68K · 2024: $48K · 2025: $118K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $190K · Travel and Lodging: $23K · Consulting Fee: $14K · Food and Beverage: $6,020 · Education: $59.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $190,420.16 |
| Travel and Lodging | $22,565.27 |
| Consulting Fee | $14,099.00 |
| Food and Beverage | $6,020.10 |
| Education | $59.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $195,034.58 | 2019-2025 | Imfinzi, Tagrisso, Datroway |
| Rigel Pharmaceuticals, INC. | $78,984.21 | 2019-2023 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $44,982.58 | 2023-2025 | Datroway, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $38,077.90 | 2019-2024 | Opdivo, Reblozyl |
| Regeneron Healthcare Solutions, INC. | $32,134.99 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $9,412.18 | 2019-2023 | Alunbrig |
| Exelixis INC. | $2,435.44 | 2019-2023 | Cabometyx |
| Morphosys, US INC. | $1,157.20 | 2021 | |
| Puma Biotechnology, INC. | $1,148.27 | 2019-2021 | |
| Eisai INC. | $672.37 | 2019-2023 | |
| Janssen Biotech, INC. | $548.79 | 2019-2023 | Erleada |
| Novartis Pharmaceuticals Corporation | $428.71 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $279.88 | 2019-2021 | |
| Lilly USA, LLC | $214.65 | 2019-2022 | |
| Galvanize Therapeutics, INC | $214.10 | 2025 | Aliya System |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.